NKX3.1 is expressed in ER-positive and AR-positive primary breast carcinomas
| Autor: | Pedram Argani, Mohammed T. Lilo, Rebecca J Asch-Kendrick, Mark A. Samols, Ashley Cimino-Mathews, Andrea P. Subhawong, Rajni Sharma, Peter B. Illei |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Pathology medicine.medical_specialty Receptor ErbB-2 Estrogen receptor Breast Neoplasms Biology urologic and male genital diseases Article Pathology and Forensic Medicine Prostate cancer Breast cancer Progesterone receptor Carcinoma medicine Biomarkers Tumor Humans skin and connective tissue diseases Aged Neoplasm Staging Homeodomain Proteins Tissue microarray Carcinoma Ductal Breast General Medicine Middle Aged medicine.disease Immunohistochemistry Tumor Burden Androgen receptor Carcinoma Lobular Receptors Estrogen Receptors Androgen Tissue Array Analysis Lymphatic Metastasis Female Breast carcinoma Receptors Progesterone Transcription Factors |
| Zdroj: | Journal of clinical pathology. 67(9) |
| ISSN: | 1472-4146 |
| Popis: | AimsNKX3.1 is an androgen-regulated tumour suppressor gene that is downregulated in prostate carcinoma. Immunohistochemistry for NKX3.1 is primarily specific for prostatic-derived tumours and tissue but is reported in a small number of breast carcinomas. NKX3.1 is also shown to inhibit estrogen receptor (ER) signalling in breast carcinoma models. Here, we investigate labelling of NKX3.1 in invasive ductal (IDC) and lobular (ILC) carcinomas of the breast with full characterisation of ER, progesterone receptor (PR), androgen receptor (AR) and Her2 status.MethodsTissue microarrays of 86 primary IDC and 37 ILC were labelled for NKX3.1. The IDC consisted of 20 luminal A, 7 luminal B, 14 Her2, and 45 triple negative carcinomas. The ILC consisted of 34 luminal A and 3 luminal B cases. NKX3.1 expression was scored as percentage nuclear labelling and labelling intensity.ResultsNuclear NKX3.1 labelling was seen in 2 IDC (2%) and 10 ILCs (27%). labelling intensity was weak in all cases (1–100% nuclear positivity). Positive NKX3.1 labelling was significantly associated with ILC (pConclusionsThis is the first study to evaluate NKX3.1 expression in breast carcinomas with known ER, PR, AR and Her2 status. Further studies are needed to evaluate what potential role NKX3.1 plays in ER and AR signalling and hormonal treatment response in breast carcinomas. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|